Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EZH2 in Myeloid Malignancies
Jenny Rinke, Andrew Chase, Nicholas C.P. Cross, et al.
Cells (2020) Vol. 9, Iss. 7, pp. 1639-1639
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

EZH2-mediated development of therapeutic resistance in cancer
Parminder Kaur, Eswar Shankar, Sanjay Gupta
Cancer Letters (2024) Vol. 586, pp. 216706-216706
Closed Access | Times Cited: 12
Exosomal RNAs and EZH2: unraveling the molecular dialogue driving tumor progression
Ahmed Hussein Zwamel, Adnan Ahmad, Farag M. A. Altalbawy, et al.
Medical Oncology (2025) Vol. 42, Iss. 4
Closed Access | Times Cited: 1
Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies
Deping Li, Xiaopeng Peng, Zhihao Hu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115982-115982
Closed Access | Times Cited: 18
Exosome miR-101–3p derived from bone marrow mesenchymal stem cells promotes radiotherapy sensitivity in non-small cell lung cancer by regulating DNA damage repair and autophagy levels through EZH2
Hongwen Sun, Runying Zhu, Xijing Guo, et al.
Pathology - Research and Practice (2024) Vol. 256, pp. 155271-155271
Closed Access | Times Cited: 6
Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics
Qichao Bao, Anil Kumar, Daqing Wu, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 6, pp. 103986-103986
Open Access | Times Cited: 6
Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity
Provas Das, Joseph H. Taube
Cancers (2020) Vol. 12, Iss. 10, pp. 2792-2792
Open Access | Times Cited: 43
Targeting metabolic reprogramming in chronic lymphocytic leukemia
Yu Nie, Xiaoya Yun, Ya Zhang, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 28
Clonal dynamics and copy number variants by single‐cell analysis in leukemic evolution of myeloproliferative neoplasms
Laura Calabresi, Chiara Carretta, Simone Romagnoli, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1520-1531
Open Access | Times Cited: 12
The prognostic and therapeutic potential of HO-1 in leukemia and MDS
Mohammad Reza Sadeghi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Predicting gene expression changes upon epigenomic drug treatment
Piyush Agrawal, Vishaka Gopalan, Monjura Afrin Rumi, et al.
F1000Research (2025) Vol. 12, pp. 1089-1089
Open Access
A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms
Ana Guijarro-Hernández, J.L. Vizmanos
Cancers (2021) Vol. 13, Iss. 5, pp. 984-984
Open Access | Times Cited: 24
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors
Alessandro Nanni Costa, Emilia Scalzulli, Ida Carmosino, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 2, pp. 189-202
Closed Access | Times Cited: 3
Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics
Nicole Santoro, Prassede Salutari, Mauro Di Ianni, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4259-4259
Open Access | Times Cited: 3
LINC00152: Potential driver oncogene in pan‐cancer
Wei Xu, Huiting Li, Ziyao Wang, et al.
Wiley Interdisciplinary Reviews - RNA (2024) Vol. 15, Iss. 3
Closed Access | Times Cited: 3
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers
Anna Sicuranza, Alessia Cavalleri, Simona Bernardi
Frontiers in Oncology (2025) Vol. 15
Open Access
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas
Franck Morschhauser, Gilles Salles, Connie Lee Batlevi, et al.
Blood Reviews (2022) Vol. 56, pp. 100988-100988
Open Access | Times Cited: 15
Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies
Anna Wolska, Piotr Smolewski
Cancers (2022) Vol. 14, Iss. 15, pp. 3778-3778
Open Access | Times Cited: 15
How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?
Alessandro Nanni Costa, Massimo Breccia
British Journal of Haematology (2023) Vol. 204, Iss. 2, pp. 434-448
Closed Access | Times Cited: 8
Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
Yilin Chen, Jing Zou, Fanjun Cheng, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 17
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes
Ali Sakhdari, Caleb A. Class, Guillermo Montalban‐Bravo, et al.
Modern Pathology (2022) Vol. 35, Iss. 9, pp. 1212-1219
Open Access | Times Cited: 10
Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Yammy Yung, Emily Lee, Hiutung Chu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 659-659
Open Access | Times Cited: 12
Novel targeted therapies in chronic myeloid leukemia
Muhammad Sameer Ashaq, Qian Zhou, Zhuoran Li, et al.
Pharmaceutical Science Advances (2024) Vol. 2, pp. 100052-100052
Open Access | Times Cited: 1
The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
Christina‐Nefeli Kontandreopoulou, Konstantinos Kalopisis, Nora‐Athina Viniou, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 7
lncRNA HOTTIP Recruits EZH2 to Inhibit PTEN Expression and Participates in IM Resistance in Chronic Myeloid Leukemia
Jing Liu, Lin Yang, Xiaojun Liu, et al.
Stem Cells International (2022) Vol. 2022, pp. 1-20
Open Access | Times Cited: 6
Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy
Johanna Rausch, Evelyn Ullrich, Michael W.M. Kühn
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top